Barely Significant
← all excerpts

Current and future immunotherapies for NSCLC.

J Hematol Oncol · 2026 · PMC13130492 · PMID 42057114

Europe PMCDOI
2
hedged sentences
0.2470
closest p · 4.9× alpha
0.2470
boldest claim

The sentences

showed a trendp = 0.247not close (p > 0.1)
Compared to CRT alone, the durvalumab combined with concurrent CRT group showed a trend toward improved PFS (median PFS: 13.8 vs. 9.4 months; HR = 0.85; 95% CI: 0.65–1.12; p = 0.247), without statistical significance [ 56 ].

also in 53,322 other papers

did not reach statistical significanceno p-value reported
Three cycles of neoadjuvant immunotherapy appear to improve MPR and pCR rates compared to two cycles; however, these increases did not reach statistical significance in the studies analysed.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.